| Turkish Journal of Cancer |
| 2009, Volume 39, Number 2, Page(s) 066-068 |
|
[ Summary ]
[ PDF ]
[ Similar Articles ]
[ Mail to Editor ]
|
| Widespread erythematous skin metastasis from breast cancer mimicking generalized drug eruption |
| GÜNGÖR UTKAN1, ABDULLAH BÜYÜKÇELİK1, AYLİN HEPER OKÇU3, UFUK AVCI2, BÜLENT YALÇIN1, FİKRİ İÇLİ1 |
1Ankara University School of Medicine, Departments of Medical Oncology, Ankara-Turkey 2Ankara University School of Medicine, Departments of Internal Medicine, Ankara-Turkey 3Ankara University School of Medicine, Departments of Pathology, Ankara-Turkey |
| Keywords: Breast cancer, erythematous skin metastasis |
| Summary |
Skin metastasis from many cancers may occur during the
course of disease. The majority of skin metastases develop
as a result of direct invasion of the cancer but sometimes,
hematogenous or lymphogenous metastases may
develop as in breast, lung, gastrointestinal tract cancers
and soft tissue sarcomas. Breast cancer is the most common
cause of skin metastases in women. The skin metastasis
of breast cancer usually develops as nodular lesions
which settle down from the primary tumor area. Herein, we
report a case of widespread erythematous skin metastasis
from breast cancer, without visceral involvement. [Turk J
Cancer 2009;39(2):66-68] |
Top
Summary
Introduction
Case Presentation
Disscussion
References
|
| Introduction |
Cutaneus metastasis may occur during the course of
many cancers. Breast, lung, and gastrointestinal cancers
are the most frequent causes of skin metastasis[ 1]. Overall
incidence of skin metastasis is about 5%[ 1]. Skin metastasis
from breast cancer is usually nodular occurring
during the late stages of the disease. Only a few reports
of erythematous widespread skin metastasis from breast
cancer have appeared in the literature[ 2]. We report a
case with erythematous widespread skin metastasis from
breast cancer without any visceral involvement. |
Top
Introduction
Case Presentation
Disscussion
References
|
| Case Presentation |
Fifty five years old, postmenopausal woman suffering
from widespread pruritic skin lesions, was admitted
to the hospital. She had left modified radical mastectomy
3 years ago for infiltrative ductal breast carcinoma.
The tumor was negative for estrogen and progesterone
receptors, and c-erb b2 expression was also immunohistochemically
negative. Following adjuvant treatment the
patient relapsed with a cutaneous nodule 2 years later. A
combination chemotherapy including docetaxel plus epirubicine
was started for palliative aim. On the 7 th day of
the third cycle, she was admitted to the hospital suffering from widespread erythematous skin lesions. The skin
lesions were pruritic and painless. She had no history
of hypersensitivity to any drug and she did not receive
any drugs other than chemotherapy regimen mentioned
above. Widespread small erythematous papular skin lesions
on entire trunk, and a nodular lesion of 3x2 cm in
diameter near the right side of the sternum were noted
on physical examination (Figure 1). Systemic dexamethasone
and oral antihistaminic were started for the clinical
diagnosis of drug eruption but there was no improvement
within 10 days of treatment. Skin biopsy was performed
from right upper back, which was far away from the area
of local recurrence, and it revealed the small solid groups
of malignant epithelial cells, predominantly located in
papillary dermis, which were consistent with the metastatic
invasion (Figure 2). There was no metastatic lesion
on computed tomographies of abdomen and thorax. Mitomycin-C plus vinorelbine were given. Following 2
cycles of this regimen, the majority of the skin lesions
were improved (Figure 3). She is still alive for fourteen
months after the diagnosis of skin metastasis, and is still
being treated with mitomycin-C and vinorelbine combination
chemotherapy.
Fig 1: Widespread erythematous skin lesions and local nodular
recurrence of breast cancer (black arrow) before mitomycin-C
plus vinorelbine treatment
Fig 2: Small solid group of malignant epithelial cells located
in the papillary dermis. The central portion of the group was
showed necrosis and apoptosis (H&E;, x200)
Fig 3: Following 2 cycles of mitomycin plus vinorelbine,
majority widespread erythematous skin lesions were improved |
Top
Introduction
Case Presentation
Disscussion
References
|
| Discussion |
Cutaneous metastasis may occur in the course of any
malignancies but diffuse involvement of the skin is not frequent.
Skin metastasis from breast cancer is usually nodular
and locally relapsing type. Furthermore skin metastasis
may associate visceral involvement in the advanced
stage of disease. Few reports of widespread erythematous
skin metastasis from breast cancer have appeared in the
literature[ 3]. Docetaxel may cause cutaneous side-effects
such as acral erythema or fixed erythematous plaque[ 2].
In our case, the skin lesions were initially thought as drug
eruption from any cause; chemotherapy and/or chemotherapy
complementary drugs such as antiemetics. To
distinguish the skin metastasis from local recurrence, the
biopsy was performed from right upper back which was
far from the area of local recurrence. Likewise, improvement
of the skin lesions by chemotherapy is also in favor
of skin metastasis from breast cancer. Other malignancies
may also present with skin lesions, but there were no
signs and symptoms supporting secondary malignancies.
The diffuse skin metastases are generally associated with
visceral metastases, but there was no visceral involvement
in our case[ 3]. The skin metastasis is treated locally or systemically while the widespread skin lesions in
a patient with ER/PR negative tumor can be treated with
systemic chemotherapy as in present case. In conclusion, widespread erythematous skin lesions resembling drug
eruptions in patients with history of breast cancer may be
due to skin metastasis as in the present case. |
Top
Introduction
Case Presentation
Discussion
References
|
| References |
|
Top
Introduction
Case Presentation
Discussion
References
|
|
[ Top ]
[ Summary ]
[ PDF ]
[ Similar Articles ]
[ Mail to Editor ]
|
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
|